Idioma:

Long-Term Administration of Enteric-Coated Mycophenolate Sodium in Kidney Transplant Patients

Salvadori, M.

Transplantation proceedings, 2005-03, Vol.37 (2), p.909-911 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Long-Term Administration of Enteric-Coated Mycophenolate Sodium in Kidney Transplant Patients
Autor: Salvadori, M.
Assuntos: Adult ; Biological and medical sciences ; Cytomegalovirus Infections - epidemiology ; Female ; Follow-Up Studies ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft Rejection - epidemiology ; Hematologic Diseases - epidemiology ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Kidney Transplantation - immunology ; Male ; Medical sciences ; Middle Aged ; Mycophenolic Acid - administration & dosage ; Mycophenolic Acid - adverse effects ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - therapeutic use ; Neoplasms - epidemiology ; Postoperative Complications - classification ; Postoperative Complications - epidemiology ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Tablets, Enteric-Coated ; Time Factors ; Tissue, organ and graft immunology
É parte de: Transplantation proceedings, 2005-03, Vol.37 (2), p.909-911
Descrição: A large-scale, controlled clinical study has shown that enteric-coated mycophenolate sodium (EC-MPS) is therapeutically equivalent to mycophenolate mofetil (MMF) in de novo renal transplant patients. Safety and efficacy outcomes from an open-label extension of this core study ( n = 122) were compared to those of the MMF arm of two well-controlled randomized studies (RAD B251, n = 141, and RAD B201, n = 150) for the 12- to 36-month posttransplant period. During this period, 33 (27%) EC-MPS patients experienced one or more drug-related adverse event. Sixteen patients (13%) discontinued the extension study due to adverse events. The incidence of all safety parameters was similar in the EC-MPS patients and the MMF-treated patients in the RAD B201 and RAD B251 studies during the 12- to 36-month posttransplant period, as was the frequency of adverse events, infections, malignancies, and hematological abnormalities. During the 24 months of the EC-MPS extension study, four patients died and two lost their graft. Biopsy-proven acute rejection (BPAR) occurred in four patients (3.3%). BPAR, graft loss, and death occurred in a similar proportion of MMF-treated patients in the RAD B201 and RAD B251 studies during months 12 to 36 posttransplant. These findings confirm the safety and efficacy of EC-MPS in maintenance transplant patients at least 1 year posttransplant and suggest that outcomes with EC-MPS are comparable to MMF in this population when used in combination with CsA-ME and steroids.
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Long-Term Administration of Enteric-Coated Mycophenolate Sodium in Kidney Transplant Patients

Salvadori, M.

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.